Alimta 500 mg/vial is a iv infusion product of Eli Lilly and Company that contains Pemetrexed. Read more Pemetrexed is indicated for: Initial treatment of patients with locally advanced or metastatic, non-squamous, non-small cell lung cancer (NSCLC) in combination with cisplatin.
There are 4 brands of Pemetrexed listed in Bangladesh. 2 of them have a lower unit price than Alimta. The lowest listed price is Alimta 100 mg/vial IV Infusion at ৳ 13372.00 per unit.
What is Alimta 500 mg/vial IV Infusion?
Alimta is a iv infusion from Eli Lilly and Company, with the generic name Pemetrexed. Treatment of patients with recurrent, metastatic non-squamous, NSCLC after prior chemotherapy, as a single agent. Pemetrexed is a thymidylate synthase inhibitor. Whether it suits you is a decision for your doctor.
Uses of Alimta
Read more Pemetrexed is indicated for: Initial treatment of patients with locally advanced or metastatic, non-squamous, non-small cell lung cancer (NSCLC) in combination with cisplatin. Maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy, as a single agent. Ask your doctor whether it is right for your condition.
How to use Alimta
It is not for self-administration at home. Complete the course exactly as prescribed. If you miss a dose, ask your doctor or pharmacist what to do.
Side effects of Alimta
The following adverse reactions are discussed in greater detail in other sections of the labeling: Myelosuppression Renal failure Bullous and exfoliative skin toxicity Interstitial pneumonitis Radiation recall Contact your doctor if you notice anything unusual after taking it. Tell your doctor if any side effect bothers you or does not go away.
Safety and precautions
Caution when used in renal or hepatic impairment. Not recommended for use in pregnancy and lactation. Pemetrexed is contraindicated in patients with a history of severe hypersensitivity reaction to Pemetrexed Tell your doctor about all the other medicines you take.
Frequently asked questions
What is Alimta used for?
Read more Pemetrexed is indicated for: Initial treatment of patients with locally advanced or metastatic, non-squamous, non-small cell lung cancer (NSCLC) in combination with cisplatin. Maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy, as a single agent.
How should I take Alimta?
It is not for self-administration at home. Complete the course exactly as prescribed.
Can Alimta cause side effects?
The following adverse reactions are discussed in greater detail in other sections of the labeling: Myelosuppression Renal failure Bullous and exfoliative skin toxicity Interstitial pneumonitis Radiation recall Contact your doctor if you notice anything unusual after taking it. Tell your doctor if any side effect bothers you or does not go away.
Initial treatment of patients with locally advanced or metastatic, non-squamous, non-small cell lung cancer (NSCLC) in combination with cisplatin.
Maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy, as a single agent.
... Read more
Pemetrexed is indicated for:
Initial treatment of patients with locally advanced or metastatic, non-squamous, non-small cell lung cancer (NSCLC) in combination with cisplatin.
Maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy, as a single agent.
Treatment of patients with recurrent, metastatic non-squamous, NSCLC after prior chemotherapy, as a single agent.
Pharmacology
Pemetrexed is a thymidylate synthase inhibitor. It works by inhibiting thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase and aminoimidazole carboxamide ribonucleotide formyltransferase, the enzymes involved in folate metabolism and DNA synthesis, thus inhibiting purine and thymidine nucleotide and protein synthesis.
Dosage & Administration
Recommended Dosage And Schedule For Non-Squamous NSCLC:
The recommended dose of Pemetrexed in combination with cisplatin for initial treatment of NSCLC in patients with a creatinine clearance (calculated by Cockcroft-Gault equation) of 45 mL/min or greater is 500 mg/m² as an intravenous infusion over 10 minutes administered prior to cisplatin on Day 1 of each 21-day cycle for up to six cycles in the absence of disease progression or unacceptable toxicity.
The recommended dose of Pemetrexed for maintenance treatment of NSCLC in patients with a creatinine clearance (calculated by Cockcroft-Gault equation) of 45 mL/min or greater is 500 mg/m² as an intravenous infusion over 10 minutes on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity after four cycles of platinum-based first-line chemotherapy.
The recommended dose of Pemetrexed for treatment of recurrent NSCLC in patients with a creatinine clearance (calculated by Cockcroft-Gault equation) of 45 mL/min or greater is 500 mg/m² as an intravenous infusion over 10 minutes on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity.
Recommended Dosage And Schedule For Mesothelioma: The recommended dose of Pemetrexed, administered in combination with cisplatin, in patients with a creatinine clearance (calculated by Cockcroft-Gault equation) of 45 mL/min or greater is 500 mg/m² as an intravenous infusion over 10 minutes on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity.
Interaction
High doses of NSAIDs and aspirin may reduce the elimination of pemetrexed; avoid usage 2 days (5 days for longer-acting NSAIDs) before, during and 2 days after treatment with pemetrexed in patients with impaired renal function. Additive GI side effects when used with SSRIs, acetylcholinesterase inhibitors, aripiprazole or ziprasidone. Additive sedation when used with psychotropics. Concurrent use with nephrotoxic drugs (e.g. aminoglycosides, loop diuretics, platinum compounds and ciclosporin) may decrease pemetrexed clearance, thus increasing the risk of toxicity. Clearance may be reduced when used with drugs that are cleared by tubular secretion e.g. probenecid and penicillin.
Contraindications
Pemetrexed is contraindicated in patients with a history of severe hypersensitivity reaction to pemetrexed
Side Effects
The following adverse reactions are discussed in greater detail in other sections of the labeling:
Myelosuppression
Renal failure
Bullous and exfoliative skin toxicity
Interstitial pneumonitis
Radiation recall
Pregnancy & Lactation
Pregnancy Category D. There is positive evidence of human fetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective).
Lactation: Advise women not to breastfeed during treatment with Pemetrexed and for 1 week after the final dose
Precautions & Warnings
Monitor CBC. Premedication with folate and vitamin B12 are recommended as prophylaxis against haematological and GI toxicity during treatment. Pre-treatment with a corticosteroid also reduces the incidence and severity of skin reactions. Caution when used in renal or hepatic impairment. Not recommended for use in pregnancy and lactation.
Overdose Effects
No drugs are approved for the treatment of Pemetrexed overdose. Based on animal studies, administration of leucovorin may mitigate the toxicities of Pemetrexed overdosage. It is not known whether pemetrexed is dialyzable.
Storage Conditions
Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F)
Alternative brands of Pemetrexed
Other brands with the same generic name, cheapest first.